Adding AI to Perjeta and Herceptin Offers Benefits for Mets

Options
Moderators
Moderators Member Posts: 25,912
edited January 2017 in Stage IV/Metastatic Breast Cancer ONLY

Adding Aromatase Inhibitor to Perjeta and Herceptin Offers Benefits for Advanced-Stage Disease in Early Study
January 18, 2017
The combination of Perjeta, Herceptin, and an aromatase inhibitor led to longer progression-free survival than only Herceptin and an aromatase inhibitor in women diagnosed with advanced-stage HER2-positive, hormone-receptor-positive disease. Read more...

· Share on FacebookShare on Twitter

Comments

  • Bestbird
    Bestbird Member Posts: 2,818
    edited January 2017

    Mods, thank you for posting this.

    Actually, the title is misleading. It's adding Perjeta, rather than an AI, that made the difference:

    The women in the PERTAIN study were randomly assigned to one of two treatments:

    • Perjeta, Herceptin, and an aromatase inhibitor -- either Arimidex (chemical name: anastrozole) or Femara (chemical name: letrozole)
    • Herceptin and an aromatase inhibitor -- either Arimidex (chemical name: anastrozole) or Femara (chemical name: letrozole)

    Progression-free survival was:

    • 18.9 months for women treated with Perjeta, Herceptin, and an aromatase inhibitor
    • 15.8 months for women treated with Herceptin and an aromatase inhibitor


    · Share on FacebookShare on Twitter

Categories